Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis. Officially authorized Japanese guidelines on this issue were revised twice at the time of approval for clinical use of direct oral anticoagulants and idarucizumab, a specific reversal agent for dabigatran. A unique recommendation in the latest Japanese clinical guides was that thrombolysis can be recommended if the time of the last dose of direct oral anticoagulants exceeds 4 hours and if commonly available anticoagulation markers are normal or subnormal, i.e., international normalized ratio of prothrombin time <1.7 and activated partial thromboplastin time <1.5 times the baseline value (≤40 seconds only as a guide). These criteria are partly supported by the findings of domestic multicenter and single-center surveys that symptomatic or asymptomatic intracranial hemorrhage following thrombolysis was rare under the conditions of the criteria. Even for dabigatran users, stroke thrombolysis can be considered without pretreatment by idarucizumab if patients meet the above criteria. If not, direct mechanical thrombectomy can be considered without pretreatment by idarucizumab or thrombolysis, and use of idarucizumab, followed immediately by thrombolysis, can be considered only when thrombectomy cannot be quickly performed. These clinical guides are practical and to some extent economical, but they have some limitations, including lack of corroborating information from sufficient numbers of relevant cases. The guides will be further modified based on the results of future research.
Abstract
Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis. Officially authorized Japanese guidelines on this issue were revised twice at the time of approval for clinical use of direct oral anticoagulants and idarucizumab, a specific reversal agent for dabigatran. A unique recommendation in the latest Japanese clinical guides was that thrombolysis can be recommended if the time of the last dose of direct oral anticoagulants exceeds 4 hours and if commonly available anticoagulation markers are normal or subnormal, i.e., international normalized ratio of prothrombin time <1.7 and activated partial thromboplastin time <1.5 times the baseline value (≤40 seconds only as a guide). These criteria are partly supported by the findings of domestic multicenter and single-center surveys that symptomatic or asymptomatic intracranial hemorrhage following thrombolysis was rare under the conditions of the criteria. Even for dabigatran users, stroke thrombolysis can be considered without pretreatment by idarucizumab if patients meet the above criteria. If not, direct mechanical thrombectomy can be considered without pretreatment by idarucizumab or thrombolysis, and use of idarucizumab, followed immediately by thrombolysis, can be considered only when thrombectomy cannot be quickly performed. These clinical guides are practical and to some extent economical, but they have some limitations, including lack of corroborating information from sufficient numbers of relevant cases. The guides will be further modified based on the results of future research.
참고문헌 (60)
- Toyoda K, "Pharmacotherapy for the secondary prevention of stroke", Drugs, 69, pp.633~647 (2009)
- Toyoda K, "Acute reperfusion therapy and stroke care in Asia after successful endovascular trials", Stroke, 46, pp.1474~1481 (2015)
- Yamaguchi T, "Alteplase at 0.6 mg", kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (JACT), 2006, pp.37, 1810~1815
- Shinohara Y, "Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision", Int J Stroke, 3, pp.55~62 (2008)
- Yasaka M, "Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation", Intern Med, 40, pp.1183~1188 (2001)
- Inoue H, "Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry", Circ J, 77, pp.2264~2270 (2013)
- Hori M, "Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: the J-ROCKET AF study", Circ J, 76, pp.2104~2111 (2012)
- Isshiki T, "Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention", Circ J, 78, pp.2926~2934 (2014)
- Takahashi H, "Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients", Clin Pharmacol Ther, 73, pp.253~263 (2003)
- Rieder MJ, "Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose", N Engl J Med, 352, pp.2285~2293 (2005)
- Shen AY, "Effect of race", ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation, 2008, pp.22, 815~825
- Guideline Committee of the Japan Stroke Society for intravenous rt-PA (alteplase) in acute ischemic stroke, "Guidelines for intravenous application of rt-PA (alteplase), October 2005", Jpn J Stroke, 27, pp.327~354 (2005)
- Minematsu K, "Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society", J Stroke Cerebrovasc Dis, 22, pp.571~600 (2013)
- Toyoda K, "Updated recommendations on acute reperfusion therapy for anticoagulated patients with ischemic stroke", Jpn J Stroke, 40, pp.123~135 (2018)
- Yamaguchi T, "Thrombolytic Therapy in Acute Ischemic Stroke III", pp.223~229 (1995), Springer-Verlag
- Ueshima S, "The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians", Thromb Haemost, 87, pp.544~546 (2002)
- Toyoda K, "Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register", Stroke, 40, pp.3591~3595 (2009)
- Mori E, "Effects of 0.6 mg", kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II), 2010, pp.41, 461~465
- Nakagawara J, "Thrombolysis with 0.6 mg", kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS), 2010, pp.41, 1984~1989
- Anderson CS, "Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke", N Engl J Med, 374, pp.2313~2323 (2016)
- Xian Y, "Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator", JAMA, 307, pp.2600~2608 (2012)
- Steiner T, "Recommendations for the emergency management of complications associated with the new direct oral anticoag ulants (DOACs), apixaban, dabigatran and rivaroxaban", Clin Res Cardiol, 102, pp.399~412 (2013)
- Diener HC, "Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment", Lancet Neurol, 12, pp.677~688 (2013)
- Sato S, "Factors associated with unfavorable outcome in minor ischemic stroke", Neurology, 83, pp.174~181 (2014)
- Hashimoto T, "Histopathologic analysis of retrieved thrombi associated with successful reperfusion after acute stroke thrombectomy", Stroke, 47, pp.3035~3037 (2016)
- Toyoda K, "Seasonal variations in neurological severity and outcomes of ischemic stroke: 5-year single-center observational study", Circ J, 82, pp.1443~1450 (2018)
- Suzuki K, "Low risk of ICH after reperfusion therapy in acute stroke patients treated with direct oral anti-coagulant", J Neurol Sci, 379, pp.207~211 (2017)
- Schiele F, "A specific antidote for dabigatran: functional and structural characterization", Blood, 121, pp.3554~3562 (2013)
- Schmohl M, "Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers", Thromb Haemost, 117, pp.269~276 (2017)
- Pollack CV Jr, "Idarucizumab for dabigatran reversal", N Engl J Med, 373, pp.511~520 (2015)
- Pollack CV Jr, "Idarucizumab for dabigatran reversal: full cohort analysis", N Engl J Med, 377, pp.431~441 (2017)
- Schafer N, "Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab: a case report", J Stroke Cerebrovasc Dis, 25, pp.e126~e127 (2016)
- Berrouschot J, "Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab", Stroke, 47, pp.1936~1938 (2016)
- Kafke W, "Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a case report", Case Rep Neurol, 8, pp.140~144 (2016)
- Gawehn A, "Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report", J Med Case Rep, 10, pp.269~ (2016)
- Schulz JG, "Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke", J Neurol Sci, 370, pp.44~ (2016)
- Mutzenbach JS, "Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab: a case report", Ann Clin Transl Neurol, 3, pp.889~892 (2016)
- Turine G, "Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer", Acta Neurol Belg, 117, pp.753~755 (2017)
- Ng FC, "Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis", J Neurol, 264, pp.591~594 (2017)
- Facchinetti R, "Rapid and well tolerated action of idarucizumab for antagonizing dabigatran in a patient needing urgent thrombolysis: a case report", Blood Coagul Fibrinolysis, 28, pp.576~579 (2017)
- Tireli D, "Systemic thrombolysis in acute ischemic stroke after dabigatran etexilate reversal with idarucizumab: a case report", J Stroke Cerebrovasc Dis, 26, pp.e123~e125 (2017)
- Cappellari M, "Intravenous thrombolysis for stroke after dabigatran reversal with idarucizumab: an update", J Thromb Thrombolysis, 43, pp.528~529 (2017)
- Kermer P, "Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany: a national case collection", Int J Stroke, 12, pp.383~391 (2017)
- Bissig D, "Acute stroke despite dabigatran anticoagulation treated with idarucizumab and intravenous tissue plasminogen activator", J Stroke Cerebrovasc Dis, 26, pp.e102~e104 (2017)
- Vosko MR, "Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases", J Thromb Thrombolysis, 43, pp.306~317 (2017)
- Alvarez Bravo G, "Intravenous fibrinolysis in ischemic stroke of large vessel after reversing effect of dabigatran with idarucizumab", J Stroke Cerebrovasc Dis, 26, pp.e192~e193 (2017)
- Agosti S, "Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report", J Med Case Rep, 11, pp.224~ (2017)
- von Wowern FA, "Idarucizumab in three patients needing urgent surgical intervention and one case of intravenous thrombolysis in ischaemic stroke", Eur J Case Rep Intern Med, 4, pp.1~3 (2017)
- Pikija S, "Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving alteplase: a systematic review of the available evidence", CNS Drugs, 31, pp.747~757 (2017)
- Tse DM, "Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumab", J Neurol Neurosurg Psychiatry, 89, pp.549~550 (2018)
- Tsai LK, "Real-world experience with idarucizumab to reverse anticoagulant effect in dabigatran-treated patients: report of 11 cases from Taiwan", J Stroke Cerebrovasc Dis, 27, pp.e27~e33 (2018)
- Lo WT, "Intravenous stroke thrombolysis after reversal of dabigatran effect by idarucizumab: first reported case in Hong Kong", Hong Kong Med J, 24, pp.81~83 (2018)
- Diener HC, "Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion", Int J Stroke, 12, pp.9~12 (2017)
- Touze E, "Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants", Eur J Neurol, 25, pp.747~e52 (2018)
- Steiner T, "Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial", Lancet Neurol, 15, pp.566~573 (2016)
- Yasaka M, "Prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: global evidence and the Japanese perspective", Circ J, 81, pp.1564~1573 (2017)
- Jalini S, "Reversal of warfarin anticoagulation with prothrombin complex concentrate before thrombolysis for acute stroke", Cerebrovasc Dis, 33, pp.597~ (2012)
- Chausson N, "Reversal of vitamin K antagonist therapy by prothrombin complex concentrate before thrombolysis for acute stroke", Cerebrovasc Dis Extra, 3, pp.95~96 (2013)
- Fontaine GV, "Alteplase for acute ischemic stroke after heparin reversal with protamine: a case report and review", Pharmacotherapy, 37, pp.e103~e106 (2017)
- Danoun O, "Thrombolysis for acute ischemic stroke after protamine reversal of heparin", Am J Ther, 25, pp.e552~e554 (2018)